<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01291212</url>
  </required_header>
  <id_info>
    <org_study_id>FIV-01</org_study_id>
    <nct_id>NCT01291212</nct_id>
  </id_info>
  <brief_title>Efficacy of Luteinizing Hormone (LH) Activity in Low Responder Patients With Transdermal Testosterone</brief_title>
  <official_title>Efficacy of LH Activity in Low Responder Patients With Transdermal Testosterone: a Randomised Controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators have previously demonstrated the utility of transdermal testosterone in in
      vitro fertilization (IVF) low responder patients. Now, the investigators want to evaluate the
      efficacy of luteinizing hormone (LH) activity added to recombinant follicular stimulating
      hormone (FSHr) during ovarian stimulation in these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies in macaques have indicated that androgens have some synergistic effects with
      follicular stimulating hormone (FSH) on folliculogenesis. Our previous clinical studies
      demonstrated the usefulness of pretreatment with transdermal testosterone in low-responder
      IVF patients.

      There is controversy on the usefulness of recombinant luteinizing hormone (LHr) added to FSHr
      in ovarian stimulation of low responder patients. Thus, our present study has been designed
      to compare ovarian stimulation with FSHr alone versus LHr added to FSHr when transdermal
      testosterone pretreatment is used.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">September 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ovarian response</measure>
    <time_frame>within 2 weeks after begining ovarian stimulation</time_frame>
    <description>number of oocytes obtained per ovarian stimulation cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>within 5 weeks (plus or minus 1 week) after embryo transfer</time_frame>
    <description>The number of clinical pregnancies expressed per embryo transfer cycles. Clinical pregnancy: a pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic pregnancy. Multiple gestational sacs are counted as one clinical pregnancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>within 5 weeks (plus/minus 1 week) after embryo transfer</time_frame>
    <description>The number of gestational sacs (observed by ultrasound examination) divided by the number of embryos transferred.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>within 9 months (plus/minus 1 month) after embryo transfer</time_frame>
    <description>The number of deliveries that resulted in at least one live born baby expressed per 100 embryo transfer cycles.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Other Complications Associated With Artificial Fertilization</condition>
  <arm_group>
    <arm_group_label>Testosterone and FSHr</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>testosterone and FSHr-LHr</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone and FSHr-LHr</intervention_name>
    <description>75U of LHr added to FSHr ovarian stimulation in IVF, when testosterone was used to improve the ovarian response</description>
    <arm_group_label>testosterone and FSHr-LHr</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>testosterone and FSHr alone</intervention_name>
    <description>FSHr alone used in ovarian stimulation in IVF, when testosterone was used to improve the ovarian response</description>
    <arm_group_label>Testosterone and FSHr</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Low responder patients: patients with previously canceled cycle or recovery of 3 or
             less oocytes

        Exclusion Criteria:

          -  FSH &gt; 12

          -  Previous ovarian surgery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>41 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Clínic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Balasch J, Fábregues F, Peñarrubia J, Carmona F, Casamitjana R, Creus M, Manau D, Casals G, Vanrell JA. Pretreatment with transdermal testosterone may improve ovarian response to gonadotrophins in poor-responder IVF patients with normal basal concentrations of FSH. Hum Reprod. 2006 Jul;21(7):1884-93. Epub 2006 Mar 3.</citation>
    <PMID>16517559</PMID>
  </reference>
  <results_reference>
    <citation>Fábregues F, Peñarrubia J, Creus M, Manau D, Casals G, Carmona F, Balasch J. Transdermal testosterone may improve ovarian response to gonadotrophins in low-responder IVF patients: a randomized, clinical trial. Hum Reprod. 2009 Feb;24(2):349-59. doi: 10.1093/humrep/den428. Epub 2008 Dec 3.</citation>
    <PMID>19054777</PMID>
  </results_reference>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2011</study_first_submitted>
  <study_first_submitted_qc>February 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2011</study_first_posted>
  <last_update_submitted>February 7, 2011</last_update_submitted>
  <last_update_submitted_qc>February 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Francisco Fábregues</name_title>
    <organization>Hospital Clínic</organization>
  </responsible_party>
  <keyword>In Vitro Fertilization</keyword>
  <keyword>Testosterone</keyword>
  <keyword>Ovarian Stimulation</keyword>
  <keyword>Luteinizing Hormone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

